Thomas Jeffrey Hargroves bought CING once, on Feb 13, 2026

Thomas Jeffrey Hargroves is a corporate individual insider who serves as a director of Cingulate Inc. (NASDAQ: CING), a clinical-stage biopharmaceutical company focused on central nervous system (CNS) disorders.( He joined the Cingulate board in connection with a $12 million private investment in public equity (PIPE) financing led by affiliates of Falcon Creek Capital Advisors, in which he was also a significant participant.( As a director, he holds indirect stakes in Cingulate through Hargroves Family Investments, LLC and has reported ownership of common stock, warrants, and stock options obtained via private placements and equity grants.( In February 2026 he acquired 97,276 shares of common stock and 77,821 warrants in a private placement, followed by a March 2026 option grant covering 15,000 shares, further aligning his interests with those of Cingulate shareholders.(

Professionally, Hargroves is best known as the founder, board member, and past president of ProPharma Group, a global consulting and services business providing medical information, pharmacovigilance, and compliance consulting to the pharmaceutical, biotechnology, and medical device industries.( He co‑founded ProPharma Group in 2001 and helped grow it into an international organization before departing the company in 2018.( Earlier in his career, he held roles in operations, quality assurance, and engineering for manufacturing and consulting companies in the drug industry, building technical and regulatory expertise that underpins his later board and investment activities.( Hargroves holds Bachelor of Science degrees in Computer Engineering and Electrical Engineering from the University of Missouri, providing a dual engineering foundation for his work in life sciences and regulated healthcare businesses.(

Written by Perplexity from public sources.